BRE NA01
Alternative Names: BRE-NA01Latest Information Update: 30 Nov 2022
At a glance
- Originator Brexogen
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants
- Mechanism of Action Exosome replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Non-alcoholic steatohepatitis
Most Recent Events
- 23 Nov 2022 Early research in Non-alcoholic steatohepatitis in South Korea, prior to November 2022 (Brexogen pipeline, November 2022)
- 23 Nov 2022 Brexogen plans preclinical trials in Non-alcoholic steatohepatitis, in Q3 2023 (Brexogen pipeline, November 2022)